Startup profile · funding coverage
Soufflé Therapeutics funding, valuation and investors
Receptor-targeted RNA medicines designed to reach tissues beyond the liver.
Keep track of Soufflé Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$135M · October 13, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$135M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Boston area, Massachusetts, United States
Investors in latest funding
Lead: Juvia Group
Other: TCG Crossover Management , BB Biotech , Fidelity Management & Research , Balyasny Asset Management , Unnamed sovereign wealth fund , ARCH Venture Partners , Bessemer Venture Partners , Amgen Ventures , Breyer Capital , The Invus Group , Janus Henderson , Leaps by Bayer , Polaris Partners , Safar Partners , TAS Partners , Temasek , Vida Ventures
Overview
Boston-area biotechnology company developing cell-targeted oligonucleotide medicines using its REMEDY receptor-mediated delivery engine. Initial programs address skeletal muscle, cardiomyocytes and muscle/metabolic disorders.
Why Soufflé Therapeutics is interesting
The investment case depends on making extrahepatic RNA delivery reproducible across programs, not simply designing a potent RNA payload. Human safety, delivery and durability data remain the decisive milestones.
Product & use cases
REMEDY identifies cell-specific internalizing receptors and uses binders to bring oligonucleotide payloads into selected cells.
- Investigational RNA medicines for muscle disorders and heart failure.
Key facts
- Closed an oversubscribed $135M Series B on October 13, 2026.
- Bayer collaboration announced January 2026 is distinct from equity financing.
Funding history (newest first)
Series B
2026-10-13 $135M- Juvia Group (lead)
- TCG Crossover Management (participant)
- BB Biotech (participant)
- Fidelity Management & Research (participant)
- Balyasny Asset Management (participant)
- Unnamed sovereign wealth fund (participant)
- ARCH Venture Partners (participant)
- Bessemer Venture Partners (participant)
- Amgen Ventures (participant)
- Breyer Capital (participant)
- The Invus Group (participant)
- Janus Henderson (participant)
- Leaps by Bayer (participant)
- Polaris Partners (participant)
- Safar Partners (participant)
- TAS Partners (participant)
- Temasek (participant)
- Vida Ventures (participant)
Source: https://www.souffletx.com/news/press-releases/101326/
Investors in our directory
Funds linked from Soufflé Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Potentially reusable receptor and ligand engineering across cell types, subject to human validation.
Competes for RNA delivery capability, clinical proof and pharma partnerships with extrahepatic RNA developers. Different tissue and disease programs are not interchangeable efficacy comparisons.
-
Avidity Biosciences adjacent
Antibody-oligonucleotide approaches to RNA delivery; different programs and development stages.
-
Dyne Therapeutics adjacent
Muscle-targeted oligonucleotide delivery; no head-to-head claim.
-
Undecimal Bio adjacent
Earlier-stage delivery of siRNA beyond the liver.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Soufflé Therapeutics's financing or category context.
FAQs about Soufflé Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.